nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—Naloxone—TLR4—esophageal cancer	0.204	0.508	CrCbGaD
Methylnaltrexone—Buprenorphine—CYP2A6—esophageal cancer	0.0657	0.164	CrCbGaD
Methylnaltrexone—Hydromorphone—PTGS1—esophageal cancer	0.0496	0.124	CrCbGaD
Methylnaltrexone—Naltrexone—ABCB1—esophageal cancer	0.0333	0.083	CrCbGaD
Methylnaltrexone—CYP2D6—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.0301	0.0502	CbGpPWpGaD
Methylnaltrexone—Buprenorphine—ABCB1—esophageal cancer	0.0244	0.061	CrCbGaD
Methylnaltrexone—Naloxone—ABCB1—esophageal cancer	0.0243	0.0605	CrCbGaD
Methylnaltrexone—CYP2D6—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.0238	0.0397	CbGpPWpGaD
Methylnaltrexone—OPRM1—G-protein activation—GNG7—esophageal cancer	0.0233	0.0389	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.0208	0.0348	CbGpPWpGaD
Methylnaltrexone—CYP2D6—CYP2E1 reactions—CYP2A6—esophageal cancer	0.0186	0.0311	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.016	0.0266	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.0147	0.0245	CbGpPWpGaD
Methylnaltrexone—OPRM1—IL4-mediated signaling events—ALOX15—esophageal cancer	0.0145	0.0241	CbGpPWpGaD
Methylnaltrexone—OPRK1—Mecp2 and Associated Rett Syndrome—SST—esophageal cancer	0.0139	0.0232	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.0138	0.023	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Xenobiotics—CYP2A6—esophageal cancer	0.0116	0.0193	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.0111	0.0185	CbGpPWpGaD
Methylnaltrexone—OPRM1—Opioid Signalling—PDE4D—esophageal cancer	0.0102	0.017	CbGpPWpGaD
Methylnaltrexone—OPRM1—Opioid Signalling—GNG7—esophageal cancer	0.00969	0.0162	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00895	0.0149	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Melatonin metabolism and effects—CYP1B1—esophageal cancer	0.00692	0.0115	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00673	0.0112	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00669	0.0112	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00664	0.0111	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00587	0.0098	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00546	0.00911	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—ADCYAP1—esophageal cancer	0.00528	0.00881	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CXCL2—esophageal cancer	0.0051	0.00852	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—GNG7—esophageal cancer	0.00489	0.00816	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.0048	0.008	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—ANXA1—esophageal cancer	0.00475	0.00792	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00473	0.0079	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—SST—esophageal cancer	0.00462	0.0077	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—GHRL—esophageal cancer	0.0045	0.00751	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—ADCYAP1—esophageal cancer	0.00446	0.00745	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CXCL2—esophageal cancer	0.00431	0.0072	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CXCL2—esophageal cancer	0.00431	0.00719	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00414	0.0069	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—GNG7—esophageal cancer	0.00413	0.00689	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—ANXA1—esophageal cancer	0.00401	0.00669	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—ANXA1—esophageal cancer	0.004	0.00668	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—SST—esophageal cancer	0.0039	0.00651	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—SST—esophageal cancer	0.00389	0.0065	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00389	0.00649	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00387	0.00645	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00382	0.00637	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—GHRL—esophageal cancer	0.0038	0.00635	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00369	0.00615	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CXCL2—esophageal cancer	0.00364	0.00607	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00363	0.00607	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.00359	0.00599	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—ADH7—esophageal cancer	0.00356	0.00593	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00342	0.00571	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—ANXA1—esophageal cancer	0.00338	0.00565	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—SST—esophageal cancer	0.00329	0.00549	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.00318	0.00531	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00313	0.00523	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—ADH1B—esophageal cancer	0.00312	0.0052	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.0031	0.00517	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00302	0.00504	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00298	0.00498	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—GNG7—esophageal cancer	0.00296	0.00494	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00295	0.00492	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—CYP26A1—esophageal cancer	0.0029	0.00484	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00289	0.00483	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00286	0.00477	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00271	0.00452	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—GSTO1—esophageal cancer	0.00269	0.0045	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.00269	0.00449	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—GSTO1—esophageal cancer	0.00266	0.00444	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00262	0.00437	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CXCL2—esophageal cancer	0.00261	0.00435	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00255	0.00426	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00252	0.00421	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—GNG7—esophageal cancer	0.0025	0.00417	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GDI2—esophageal cancer	0.00248	0.00415	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—ANXA1—esophageal cancer	0.00242	0.00405	CbGpPWpGaD
Methylnaltrexone—OPRM1—IL4-mediated signaling events—PIK3CA—esophageal cancer	0.00236	0.00394	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—SST—esophageal cancer	0.00236	0.00394	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—GHRL—esophageal cancer	0.0023	0.00384	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00229	0.00382	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CXCL2—esophageal cancer	0.0022	0.00368	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—ALDH2—esophageal cancer	0.0022	0.00367	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GDI2—esophageal cancer	0.0021	0.0035	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—GSTT1—esophageal cancer	0.00209	0.00349	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—CYP2A6—esophageal cancer	0.00207	0.00345	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—ANXA1—esophageal cancer	0.00205	0.00342	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—SST—esophageal cancer	0.00199	0.00333	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.00196	0.00327	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—GHRL—esophageal cancer	0.00194	0.00324	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKAP13—esophageal cancer	0.00192	0.00321	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KMT2D—esophageal cancer	0.0018	0.003	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PDE4D—esophageal cancer	0.00176	0.00293	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKAP13—esophageal cancer	0.00175	0.00291	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—GNG7—esophageal cancer	0.00167	0.00279	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.00166	0.00278	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00164	0.00274	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKAP13—esophageal cancer	0.00162	0.00271	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADCYAP1—esophageal cancer	0.0016	0.00267	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PDE4D—esophageal cancer	0.0016	0.00266	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.00157	0.00261	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.00154	0.00258	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—GNG7—esophageal cancer	0.00152	0.00253	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KMT2D—esophageal cancer	0.00152	0.00253	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PDE4D—esophageal cancer	0.00149	0.00248	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKAP13—esophageal cancer	0.00148	0.00246	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCL2—esophageal cancer	0.00147	0.00246	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—WWOX—esophageal cancer	0.00146	0.00244	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—GNG7—esophageal cancer	0.00141	0.00236	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FKBP1A—esophageal cancer	0.00139	0.00232	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—ANXA1—esophageal cancer	0.00137	0.00229	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—WIF1—esophageal cancer	0.00136	0.00227	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADCYAP1—esophageal cancer	0.00135	0.00226	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PDE4D—esophageal cancer	0.00135	0.00225	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCL2—esophageal cancer	0.00134	0.00223	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—SST—esophageal cancer	0.00133	0.00222	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—GHRL—esophageal cancer	0.0013	0.00217	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GNG7—esophageal cancer	0.00128	0.00214	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CSNK1A1—esophageal cancer	0.00126	0.0021	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCL2—esophageal cancer	0.00125	0.00208	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—ANXA1—esophageal cancer	0.00124	0.00208	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—WWOX—esophageal cancer	0.00124	0.00206	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—SST—esophageal cancer	0.00121	0.00202	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—GHRL—esophageal cancer	0.00118	0.00197	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FKBP1A—esophageal cancer	0.00118	0.00196	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PFN1—esophageal cancer	0.00117	0.00196	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—ANXA1—esophageal cancer	0.00116	0.00193	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—WIF1—esophageal cancer	0.00115	0.00192	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCL2—esophageal cancer	0.00113	0.00189	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—SST—esophageal cancer	0.00113	0.00188	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—GHRL—esophageal cancer	0.0011	0.00183	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CSNK1A1—esophageal cancer	0.00106	0.00177	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ELMO1—esophageal cancer	0.00106	0.00176	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—ANXA1—esophageal cancer	0.00105	0.00175	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKAP13—esophageal cancer	0.00103	0.00172	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—SST—esophageal cancer	0.00102	0.00171	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GHRL—esophageal cancer	0.000997	0.00166	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PFN1—esophageal cancer	0.000993	0.00166	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000952	0.00159	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PDE4D—esophageal cancer	0.000943	0.00157	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GNG7—esophageal cancer	0.000897	0.0015	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ELMO1—esophageal cancer	0.000892	0.00149	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKAP13—esophageal cancer	0.000872	0.00145	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000841	0.0014	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000841	0.0014	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—XIAP—esophageal cancer	0.000841	0.0014	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000804	0.00134	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PDE4D—esophageal cancer	0.000797	0.00133	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CTNNA1—esophageal cancer	0.000795	0.00133	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL2—esophageal cancer	0.00079	0.00132	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GNG7—esophageal cancer	0.000758	0.00127	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PSME1—esophageal cancer	0.000738	0.00123	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PSME2—esophageal cancer	0.000738	0.00123	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ANXA1—esophageal cancer	0.000735	0.00123	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000715	0.00119	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CA1—esophageal cancer	0.000715	0.00119	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SST—esophageal cancer	0.000715	0.00119	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—XIAP—esophageal cancer	0.000711	0.00119	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GHRL—esophageal cancer	0.000697	0.00116	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOTCH3—esophageal cancer	0.000697	0.00116	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FBXW7—esophageal cancer	0.000685	0.00114	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CTNNA1—esophageal cancer	0.000672	0.00112	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL2—esophageal cancer	0.000668	0.00111	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CA2—esophageal cancer	0.000654	0.00109	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOTCH2—esophageal cancer	0.000625	0.00104	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PSME2—esophageal cancer	0.000624	0.00104	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PSME1—esophageal cancer	0.000624	0.00104	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ANXA1—esophageal cancer	0.000621	0.00104	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000608	0.00101	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000608	0.00101	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SST—esophageal cancer	0.000604	0.00101	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GHRL—esophageal cancer	0.000589	0.000983	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH3—esophageal cancer	0.000589	0.000983	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FBXW7—esophageal cancer	0.000579	0.000967	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TGFBR2—esophageal cancer	0.000554	0.000925	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000533	0.00089	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH2—esophageal cancer	0.000528	0.000881	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SMAD4—esophageal cancer	0.000525	0.000876	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TYMP—esophageal cancer	0.00051	0.00085	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000496	0.000827	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000483	0.000806	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFBR2—esophageal cancer	0.000468	0.000782	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.000461	0.000769	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TPI1—esophageal cancer	0.000461	0.000769	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SMAD4—esophageal cancer	0.000443	0.00074	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALDOB—esophageal cancer	0.000442	0.000737	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HIF1A—esophageal cancer	0.000429	0.000717	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GAPDH—esophageal cancer	0.000425	0.00071	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CRABP1—esophageal cancer	0.000421	0.000703	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KDR—esophageal cancer	0.000411	0.000685	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GNG7—esophageal cancer	0.000401	0.000669	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOTCH1—esophageal cancer	0.000387	0.000646	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALDH2—esophageal cancer	0.000376	0.000627	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HIF1A—esophageal cancer	0.000363	0.000606	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTT1—esophageal cancer	0.000357	0.000596	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP2A6—esophageal cancer	0.000353	0.000589	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CREBBP—esophageal cancer	0.000351	0.000585	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KDR—esophageal cancer	0.000347	0.000579	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—EGFR—esophageal cancer	0.000345	0.000575	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ENO1—esophageal cancer	0.000335	0.000559	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS1—esophageal cancer	0.000335	0.000559	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PSME1—esophageal cancer	0.00033	0.000551	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PSME2—esophageal cancer	0.00033	0.000551	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000329	0.00055	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH1—esophageal cancer	0.000327	0.000546	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOS3—esophageal cancer	0.000314	0.000524	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CA—esophageal cancer	0.000299	0.000499	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CREBBP—esophageal cancer	0.000296	0.000495	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ERBB2—esophageal cancer	0.000294	0.00049	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—EGFR—esophageal cancer	0.000291	0.000486	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP1B1—esophageal cancer	0.000285	0.000475	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000278	0.000465	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP19A1—esophageal cancer	0.000268	0.000447	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOS3—esophageal cancer	0.000265	0.000443	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCND1—esophageal cancer	0.000259	0.000433	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CA—esophageal cancer	0.000253	0.000422	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CDKN1A—esophageal cancer	0.000251	0.000419	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ERBB2—esophageal cancer	0.000248	0.000414	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HMOX1—esophageal cancer	0.000244	0.000408	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EP300—esophageal cancer	0.000239	0.000399	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCB1—esophageal cancer	0.000234	0.000391	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCND1—esophageal cancer	0.000219	0.000366	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CDKN1A—esophageal cancer	0.000212	0.000354	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MYC—esophageal cancer	0.000208	0.000347	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EGFR—esophageal cancer	0.000204	0.00034	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EP300—esophageal cancer	0.000202	0.000337	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CA—esophageal cancer	0.000177	0.000295	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MYC—esophageal cancer	0.000176	0.000294	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EGFR—esophageal cancer	0.000172	0.000287	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TP53—esophageal cancer	0.000171	0.000285	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CREBBP—esophageal cancer	0.000157	0.000262	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CA—esophageal cancer	0.000149	0.000249	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TP53—esophageal cancer	0.000144	0.000241	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NOS3—esophageal cancer	0.00014	0.000234	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS2—esophageal cancer	0.000128	0.000214	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—EP300—esophageal cancer	0.000107	0.000178	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CA—esophageal cancer	7.89e-05	0.000132	CbGpPWpGaD
